Inhibitex acquired by Bristol-Myers Squibb

被引：0

作者：

Bruce, Issac

机构：

来源：

BIOANALYSIS | 2012年 / 4卷 / 04期

关键词：

D O I：

暂无

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

收藏

页码：351 / 351

页数：1

相关论文

共 50 条

[31] Bristol-Myers Squibb swallows last of antibody pioneers
Malorye Allison
Nature Biotechnology, 2009, 27 : 781 - 783
[32] Bristol-Myers Squibb locks into novel autoimmune strategy
Garber, Ken
NATURE BIOTECHNOLOGY, 2016, 34 (06) : 577 - 579
[33] Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall
Dorey, Emma
NATURE BIOTECHNOLOGY, 2010, 28 (11) : 1137 - 1138
[34] Bristol-Myers Squibb swallows last of antibody pioneers
Allison, Malorye
NATURE BIOTECHNOLOGY, 2009, 27 (09) : 781 - 783
[35] Technology evaluation: Ipilimumab, Medarex/Bristol-Myers Squibb
Morse, MA
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2005, 7 (06) : 588 - 597
[36] Bristol-Myers Squibb Plans Expansion of Biologics Facility
Van Arnum, Patricia
BIOPHARM INTERNATIONAL, 2013, 26 (05) : 10 - 10
[37] Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall
Emma Dorey
Nature Biotechnology, 2010, 28 : 1137 - 1138
[38] Bristol-Myers Squibb locks into novel autoimmune strategy
Ken Garber
Nature Biotechnology, 2016, 34 : 577 - 578
[39] Bristol-Myers Squibb wins breast implant case
Reisch, M
CHEMICAL & ENGINEERING NEWS, 1996, 74 (06) : 9 - 9
[40] Bristol-Myers Squibb sells ConvaTec business unit
不详
WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE, 2008, 20 (06): : A22 - A22

← 1 2 3 4 5 →